首页> 外文期刊>Experimental and therapeutic medicine >Correlations of chemokine CXCL16 and TNF-alpha with coronary atherosclerotic heart disease
【24h】

Correlations of chemokine CXCL16 and TNF-alpha with coronary atherosclerotic heart disease

机译:趋化因子CXCL16和TNF-α与冠状动脉粥样硬化心脏病相关性的相关性

获取原文
获取原文并翻译 | 示例
           

摘要

This study determined the correlations of CXC ligand 16 (CXCL16) and tumor necrosis factor-alpha (TNF-alpha) levels with coronary atherosclerotic heart disease (CAHD) and screened for new clinical markers for the prognosis and treatment of the disease. Eighty patients with coronary heart disease and 50 healthy subjects were enrolled into a CAHD or healthy control group, respectively. Computed tomography (CT) coronary angiography and Gensini integral were used to classify plaques and evaluate patients with coronary heart disease. The serum levels of CXCL16 and TNF-alpha of subjects in each group were detected by enzyme-linked immunosorbent assays (ELISA), and the correlation between levels and clinical markers (such as blood pressure, glucose, lipid and heart rate) and the severity of disease were analyzed. Our results showed the serum levels of CXCL16 and TNF-alpha were significantly higher in the CAHD group than those in the CK group. The serum CXCL16 levels of the CAHD group patients with plaques were distinctly higher than those of the CADH group patients without plaques, but there were no significant difference in serum TNF-alpha levels between these two groups of patients. The level of CXCL16 had a significantly positive correlation with the severity of disease, but there was no significant correlation between TNF-alpha level and the severity of disease. Also, there was no significant correlation between the CXCL16 levels and blood pressure, blood glucose, heart rate, total cholesterol, triglyceride or high-density lipoprotein cholesterol, but there was a clear correlation with the low-density lipoprotein cholesterol. Finally no significant correlations were found between TNF-alpha levels and each of the clinical markers studied. Based on our findings, the levels of CXCL16 and TNF-alpha in the patients with coronary heart disease were abnormally increased and the level of CXCL16 correlated closely with the severity of disease. These markers seem to be reliable biological markers for prognosis and disease evaluation in coronary heart disease patients.
机译:该研究确定了CXC配体16(CXC116)和肿瘤坏死因子-α(TNF-α)水平与冠状动脉粥样硬化心脏病(CAHD)的相关性,并筛选新的临床标志物,用于预后和治疗该疾病。患有冠心病和50名健康受试者的八十名患者分别注册到CAHD或健康对照组中。计算断层扫描(CT)冠状动脉造影和Gensini整体用于分类斑块并评估冠心病患者。通过酶联免疫吸附试验(ELISA)检测每组受试者的CXC116和TNF-α的血清水平,以及水平和临床标志物(例如血压,葡萄糖,脂质和心率)和严重程度之间的相关性分析了疾病。我们的结果表明,CAHC组的CXCL16和TNF-α的血清水平高于CK组的CXC组显着高。 CAHD组患者的血清CXCL16水平明显高于CADH组患者,没有斑块,但这两组患者之间的血清TNF-α水平没有显着差异。 CXCL16的水平与疾病的严重程度有显着阳性相关性,但TNF-α水平与疾病严重程度之间没有显着相关性。此外,CXCL16水平和血压之间没有显着的相关性,血糖,心率,总胆固醇,甘油三酯或高密度脂蛋白胆固醇,但与低密度脂蛋白胆固醇呈明显相关。最后没有发现TNF-α水平和研究的每个临床标记之间没有显着相关性。基于我们的研究结果,冠心病患者CXCL16和TNF-α的水平异常增加,CXCL16的水平与疾病严重程度密切相关。这些标志物似乎是可靠的生物学标志物,用于冠心病患者的预后和疾病评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号